The literature on ibogaine’s effects continues to grow, including its impact on opiate withdrawal and craving, mood symptoms, and trauma-related responses. To fully inform clinicians of this rapidly evolving field, it is critical that they are aware of emerging dosing strategies and protocols and associated adverse effects. A search of PubMed/MEDLINE, Embase, and PsycInfo was conducted for human studies on ibogaine, noribogaine, or 5-MeO-DMT. A prespecified strategy used controlled vocabulary and keyword search terms for substance-use, mood/anxiety, and trauma-related disorders. Randomized trials, microdosing, and sequential treatments were prioritized. Only three RCTs exist: a double-blind pilot in 20 adults with cocaine dependence; an ascending-dose trial in 36 healthy volunteers; and a crossover trial in 27 opioid-dependent patients. Microdosing has been associated with reductions in withdrawal and mood and anxiety benefits but remains anecdotal. Sequential protocols incorporating ibogaine with 5-MeO-DMT or magnesium produced profound reductions in post-traumatic stress, depression, anxiety, and insomnia; however, these derive from retrospective questionnaires or open-label trials. Initial evidence suggests that ibogaine may reduce withdrawal, craving, and psychiatric symptoms, while microdosing and sequential treatment appear promising. The evidence base thus far is limited and consists of small early-phase RCTs. Ibogaine’s cardiovascular toxicity and narrow therapeutic margin require caution.
